Bill Gates Is Fighting Alzheimer’s Disease with the Help of AI

Bill Gates, co-founder of Microsoft, has just announced a new global competition called the Alzheimer’s Insights AI Prize. This initiative offers a $1 million prize (approximately CZK 22.5 million) for developing AI capable of autonomously analyzing decades of Alzheimer’s disease research data. The competition is funded through Gates Ventures and organized by the Alzheimer’s Disease Data Initiative, which was founded in 2020. Its goal is to accelerate breakthroughs from global patient data, with the winning tool made freely available to all scientists worldwide. Applications opened on August 19 and are open to a wide range of participants, including individual AI engineers, major technology labs, computational biomedicine experts, clinical specialists, and Alzheimer’s disease researchers.

Details of the Alzheimer’s Insights AI Prize

The competition is seeking AI agents capable of independently planning, reasoning, and acting to uncover new findings from extensive data on Alzheimer’s disease and related dementias. According to Niranjan Bose, interim executive director of the Alzheimer’s Disease Data Initiative and managing director of health and life sciences at Gates Ventures, this is a call for the global innovation ecosystem to act quickly. AI has the potential to transform the pace and scale of dementia research, which is crucial because more than 7 million people in the United States are living with Alzheimer’s disease, and that number is expected to rise as life expectancy increases. The winning team will not only receive the prize, but its tool will also be integrated into the AD Workbench online research environment, where it will be freely available to scientists. Semifinalists will be announced in December 2025, and finalists will compete in March 2026 at the Alzheimer’s and Parkinson’s Diseases Conference in Copenhagen.

Why AI Could Transform Alzheimer’s Research

Alzheimer’s disease is complex, with many possible causes and biological pathways that have long hindered scientists. Agentic AI, as explained by Gregory Moore, senior advisor at Gates Ventures and the Alzheimer’s Disease Data Initiative, is ideal for these challenges because it can autonomously process vast amounts of data and uncover insights that people might overlook. AI could shift research from reactive to predictive—identifying new biomarkers for the early stages of the disease, optimizing clinical trial design, and uncovering unexpected opportunities to develop or repurpose drugs. The competition emphasizes that the winning solution must deliver a significant leap in the speed, scale, or reach of dementia research, and all tools developed through it will be made publicly available to support open science.

Bill Gates’s Personal Motivation

For Bill Gates, this competition is personal—his father died of Alzheimer’s disease in 2020 at the age of 94. Gates has previously invested from his personal fortune, estimated at approximately $118.3 billion, including $50 million in new treatments, another $50 million in clinical trials and early detection, and $30 million in an initiative focused on improving diagnosis. The Alzheimer’s Disease Data Initiative, which he helped establish, provides researchers with secure data sharing, analytical tools, and collaborative resources free of charge. The competition is part of a broader movement using AI to advance the diagnosis, treatment, and understanding of neurodegenerative diseases.

Demis Hassabis’s View of the Future of AI in Medicine

Demis Hassabis, CEO of Google DeepMind, sees the potential for AI to cure all diseases within the next decade. In an interview with CBS News, he described how AI models such as the one he developed with John Jumper to determine protein structures accelerated the mapping of 200 million proteins in a single year—a process that previously took years. Hassabis believes AI could reduce drug development from ten years and billions of dollars to months or weeks, revolutionizing human health. Gates is betting that AI agents can help accelerate Alzheimer’s disease research right now, while the open-access requirement ensures that discoveries benefit global research rather than remaining locked behind corporate walls.

Competition Notes

The competition is open to AI and machine learning engineers, computational biomedicine experts, technology companies, clinical specialists, and Alzheimer’s disease researchers. No further details about specific evaluation criteria or participating teams have been released, but official materials and applications are available on the Alzheimer’s Disease Data Initiative website. This initiative underscores how AI can bring radical changes to the fight against diseases such as Alzheimer’s and opens the door to broad collaboration.